Figure 3
From: Unveiling some FDA-approved drugs as inhibitors of the store-operated Ca2+ entry pathway
Effects of selected compounds on CRAC current. (a) RBL-1 cells were pre-treated for ~20 min with BTP2 (10 μM), teriflunomide (20 μM) and tolvaptan (20 μM) whilst the control cells received DMSO. Representative current-voltage plots (mean ± S.E.M) from whole-cell recording of at least four different cells in each condition are shown. (b) Bar graphs (mean ± S.E.M) showing current densities at −100 mV holding potential under each condition. The statistical comparison among the values for all conditions was determined using one way ANOVA followed by Dunnett’s test.
